Loading
Loading
Curated from FDA notices, manufacturer press releases, peer-reviewed studies, and trusted outlets. Direct source links on every item. Practical context for researchers — not academic abstracts.
New data from Lilly suggests patients who stop GLP-1 agonists regain significant weight, supporting the case for long-term maintenance dosing strategies rather than finite treatment courses.
Read source →Survodutide (GLP-1/glucagon dual agonist) achieved weight loss analysts described as 'Wegovy-like' and showed signs of muscle mass preservation — a potential differentiator from existing GLP-1 drugs.
Read source →The FDA has scheduled an advisory committee meeting on unapproved peptides used in compounding, signalling a potential policy shift following pressure from HHS Secretary RFK Jr.
Read source →Lilly's orforglipron became the first daily GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions, removing a key compliance barrier of existing oral GLP-1 options.
Read source →STAT News opinion piece on the rise of consumer peptide use — arguing that distrust of pharmaceutical medicine is driving patients toward compounds with weaker evidence bases.
Read source →In a notable regulatory shift, the FDA has reclassified several unapproved peptides previously barred from compounding, ahead of a formal advisory committee review on their potential compounding use.
Read source →Retatrutide lowered HbA1c by an average of 1.7–2.0% across doses at 40 weeks in TRANSCEND-T2D-1, meeting its primary endpoint and advancing the compound toward potential regulatory submission.
Read source →Retatrutide's Phase 3 diabetes data show the compound may be a meaningful advance on existing GLP-1 drugs — cutting blood sugar and body weight significantly in the TRANSCEND-T2D-1 study.
Read source →Eli Lilly issued a public warning after uncovering significant levels of impurity in compounded tirzepatide products mixed with vitamin B12, urging patients to avoid these formulations.
Read source →Eli Lilly's Phase 3 TRIUMPH-4 trial, evaluating retatrutide in patients with obesity, reported positive topline results — further supporting retatrutide's position as the most potent weight-loss agent in late-stage development.
Read source →Where this news comes from
Capital Peptides aggregates research news from primary sources only — FDA Federal Register notices, manufacturer investor releases, peer-reviewed studies on PubMed / NEJM / Lancet, and trusted industry outlets (BioPharma Dive, STAT, AJMC, HCPLive). We summarize in plain English; click the source link to verify. No vendor sponsorship influences inclusion.